获批NMPA！新一代血糖监测系统

Core Viewpoint - The approval of the new generation continuous glucose monitoring system, Silicore Dynamic GS3, by the NMPA marks a significant development for domestic medical device companies, allowing them to compete in a market traditionally dominated by multinational corporations [2][3]. Market Overview - The CGM market is experiencing rapid growth, with the market size in China projected to reach approximately 1.54 billion yuan in 2025, reflecting a year-on-year increase of 45.8%, significantly outpacing the traditional blood glucose meter market, which grows at about 10% [9]. - Factors driving this growth include an increasing number of diabetes patients, greater acceptance of continuous glucose monitoring by hospitals, expanded use of insulin pumps and closed-loop systems, and rising demand for home-based chronic disease management [12]. Technological Competition - The core of CGM technology competition lies in the sensor materials and algorithm models, which form the main technical barriers. The sensors must maintain stable glucose detection accuracy while operating subcutaneously for several days [4][6]. - The Silicore Dynamic GS3 has achieved key performance indicators that meet the international iCGM standards, which are typically used for continuous glucose monitoring devices linked with insulin pumps or automated insulin delivery systems [6]. Company Background - Silicore Bionic, established in 2015 and headquartered in Shenzhen, China, focuses on the research and production of continuous glucose monitoring technology. Its main products include the Silicore Dynamic series for continuous blood glucose monitoring and management [11]. - As of the end of 2025, the company has over 3 million cumulative users across more than 100 countries and regions, and it has initiated the IPO process [11]. Opportunities and Challenges for Domestic Manufacturers - Domestic CGM companies, including Silicore Bionic, face challenges such as the need for clinical data accumulation, as international competitors often have over a decade of clinical application data [15]. - Brand trust and distribution channels remain critical, as hospitals and patients tend to favor established brands. Additionally, the future competition will not only focus on sensors but also on the integration of insulin pumps, digital platforms, and closed-loop systems [16].